Healthcare >> CEO Interviews >> October 5, 2000
DR. SANDRA NUSINOFF LEHRMAN is President and Chief Executive Officer of
Genzyme Transgenics Corporation. Dr. Lehrman was a Founder of Triangle
Pharmaceuticals in Durham, NC, where she served as Vice President of
Drug Development. During her 10-year tenure as an executive at Burroughs
Wellcome, Dr. Lehrman held several posts, including that of Vice
President, Infectious Diseases, Immunology and Biotechnology;
International Director of Biotechnology for Wellcome PLC; and Vice
President and General Manager of BW Manufacturing, Inc. Dr. Lehrman
holds numerous patents as a recognized leader in the area of antiviral
therapeutics, and is an inventor of the use of Retrovir( (AZT) for the
prophylaxis and treatment of retroviral infections. She is currently a
member of the AIDS Research Advisory Committee, National Institute of
Arthritis and Infectious Diseases (NIAID). She also serves as a member
of the Brown University Corporation Committee on Biomedical Affairs and
has served as a Director of the Rhode Island Center for Cellular
Medicine. Dr. Lehrman received her Doctor of Medicine Degree from Brown
University, served her residency in Pediatrics at Massachusetts General
Hospital and completed her post-doctoral fellowship in Infectious
Diseases at Duke University Medical Center. Profile
Dr. Lehrman: Genzyme Transgenics is a company that is dedicated to the
production of medicines from milk. Our core technology is
